Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-16T06:29:06.968Z Has data issue: false hasContentIssue false

Long–term survival in trial of medium–titre Edmonston–Zagreb measles vaccine in Guinea–Bissau: five–year follow–up

Published online by Cambridge University Press:  15 May 2009

P. Aaby*
Affiliation:
Epidemiology Research Unit, Statens Seruminstitut, Copenhagen, Denmark
I. M. Lisse
Affiliation:
Department of Pathology, Hvidovre University Hospital, Copenhagen, Denmark
H. Whittle
Affiliation:
Medical Research Council Laboratories, Fajara, The Gambia
K. Knudsen
Affiliation:
Epidemiology Research Unit, Statens Seruminstitut, Copenhagen, Denmark
J. Thaarup
Affiliation:
International Medical Cooperation Committee, Copenhagen, Denmark
A. Poulsen
Affiliation:
International Medical Cooperation Committee, Copenhagen, Denmark
M. Sodemann
Affiliation:
International Medical Cooperation Committee, Copenhagen, Denmark
M. Jakobsen
Affiliation:
International Medical Cooperation Committee, Copenhagen, Denmark
L. Brink
Affiliation:
International Medical Cooperation Committee, Copenhagen, Denmark
U. Gansted
Affiliation:
International Medical Cooperation Committee, Copenhagen, Denmark
A. Permin
Affiliation:
International Medical Cooperation Committee, Copenhagen, Denmark
T. G. Jensen
Affiliation:
International Medical Cooperation Committee, Copenhagen, Denmark
H. Andersen
Affiliation:
Danchurchaid, Bissau
M. C. da Silva
Affiliation:
Maternal and Child Health Programme, Ministry of Public Health, Guinea-Bissau
*
*Peter Aaby, Epidemiology Research Unit, Artillerivej 5, 2300 Copenhagen S, Denmark.
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

A trial of protective efficacy which compared medium–titre Edmonston-Zagreb (EZ) measles vaccine (104.6 p.f.u.) from the age of 4 months with the standard Schwarz (SW) measles vaccine given from the age of 9 months was started in an urban community in Guinea-Bissau in 1985. Because trials of high–titre measles vaccine have found increased mortality among female recipients, we examined whether EZ medium–titre vaccine was associated with any long-term impact on mortality, suppression of T–cells, or growth. The mortality rate ratio over 5 years of follow–up was 1.12 for EZ children compared with children in the standard group (P = 0.63). Seventy–five percent of the children still residing in the area at 5 years of age took part in an immunological and anthropometric examination. There was no difference in T–cell subsets between the two groups. There was no difference in mid–upper–arm circumference, but EZ children were significantly shorter than the children in the standard group. In conclusion, medium–titre EZ was not associated with reduced survival or persistent immunosuppression.

Type
Research Article
Copyright
Copyright © Cambridge University Press 1994

References

REFERENCES

Aaby, P, Knudsen, K, Jensen, TG et al. , Measles incidence, vaccine efficacy and mortality in two urban African areas with high vaccination coverage. J Infect Dis 1990; 162: 1043–8.CrossRefGoogle ScholarPubMed
Aaby, P, Clements, J. Measles immunization research. A review. Bull WHO 1989; 67: 443–8.Google ScholarPubMed
Loening, WEK, Coovadia, HM. Age–specific occurrence rates of measles in urban, peri–urban, and rural environments: implications for time of vaccination. Lancet 1983; ii: 324–6.CrossRefGoogle Scholar
Dabis, F, Sow, A, Waldman, RJ et al. , The epidemiology of measles in a partially vaccinated population in an African city: implications for immunization programmes. Am J Epidemiol 1988; 127: 171–8.CrossRefGoogle Scholar
Whittle, H, Hanlon, P, O'Neill, K et al. , Trial of high–dose Edmonston–Zagreb measles vaccine in The Gambia: antibody response and side-effects. Lancet 1988; ii: 811–14.CrossRefGoogle Scholar
Tidjani, O, Grunitsky, B, Guerin, N et al. , Serological effects of Edmonston–Zagreb, Schwarz, and AIK–C measles vaccine strains given at ages 4–5 or 8–10 months. Lancet 1989; ii: 1357–60.CrossRefGoogle Scholar
Markowitz, LE, Sepulveda, J, Diaz-Ortega, JL et al. , Immunization of six–month–old infants with different doses of Edmonston–Zagreb and Schwarz measles vaccines. N Engl J Med 1990; 322: 580–7.CrossRefGoogle ScholarPubMed
Aaby, P, Jensen, TG, Hansen, HL et al. , Trial of high–dose Edmonston–Zagreb measles vaccine in Guinea–Bissau: protective efficacy. Lancet 1988; ii: 809–11.CrossRefGoogle Scholar
9.Expanded Programme on Immunization: Global Advisory Group. Weekly Epidem Rec 1990; 65: 511.Google Scholar
Whittle, HC, Campbell, H, Rahman, S, Armstrong, JRM. Antibody persistence in Gambian children after high–dose Edmonston–Zagreb measles vaccine. Lancet 1990; 336: 1046–8.CrossRefGoogle ScholarPubMed
Aaby, P, Knudsen, K, Whittle, H et al. , Long–term survival after Edmonston–Zagreb measles vaccination: increased female mortality. J Pediatr 1993; 122: 904–8.CrossRefGoogle ScholarPubMed
Aaby, P, Samb, B, Simondon, Knudsen K et al. , Divergent mortality for male and female recipients of low-titre and high–titre measles vaccines in rural Senegal. Am J Epidemiol 1993; 138: 746–55.CrossRefGoogle Scholar
Halsey, N. Increased mortality following high titre measles vaccines: too much of a good thing. J Pediatr Infect Dis 1993: 12: 462–5.CrossRefGoogle Scholar
14.Expanded Programme on Immunization. Consultation on studies involving high titre measles vaccines. Weekly Epidemiol Rec 1992; 67: 357–61.Google Scholar
Whittle, HC, Mann, G, Eccles, M et al. , Effects of dose and strain of vaccine on success of measles vaccination of infants aged 4–5 months. Lancet 1988; 1: 963–6.CrossRefGoogle ScholarPubMed
Hall, A, Aaby, P. Tropical trials and tribulations. Int J Epidemiol 1990; 19: 777–81.CrossRefGoogle ScholarPubMed
Lisse, IM, Whittle, H, Aaby, P, Normark, M, Gyhrs, A, Ryder, LP. Labelling of T–cell subsets under field conditions in tropical countries. Adaptation of the immuno–alkaline phosphatase staining method for blood–smears. J Immunol Methods 1990; 129: 4953.CrossRefGoogle ScholarPubMed
Cox, DR, Oakes, D. Analysis of survival data. London: Chapman and Hall, 1984.Google Scholar
Aaby, P, Andersen, M, Sodemann, , Jakobsen, M, Gomes, J, Fernandes, M. Reduced childhood mortality following standard measles vaccination at 4–8 months compared to 9–11 months of age. BMJ 1993; 307: 1308–11.CrossRefGoogle ScholarPubMed